[O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD. (1st July 2017)